Retroperitoneal Lymph Node Dissection (RPLND)

Retroperitoneal lymph node dissection is a surgical procedure to remove lymph nodes located behind the abdominal cavity, in the area called the retroperitoneum (the space behind the lining of the abdomen, near the spine, kidneys, and major blood vessels). It is most commonly performed for testicular cancer but is sometimes used in peritoneal mesothelioma and other abdominal cancers to assess or remove disease that has spread to these deep lymph nodes.

Origin

The term combines "retro-" (behind) and "peritoneum" (the abdominal lining), from Greek and Latin roots. RPLND was developed and refined as a cancer staging and treatment procedure in the mid-20th century, becoming standardized for testicular cancer in the 1970s and 1980s before being adapted for other intra-abdominal malignancies.

Significance in Asbestos Context

For patients with peritoneal mesothelioma, the form of asbestos-related cancer that develops in the abdominal lining, lymph node involvement is an important prognostic factor and can affect surgical planning. Although the mainstay of treatment for peritoneal mesothelioma is cytoreductive surgery (CRS) combined with HIPEC, surgeons may sample or remove retroperitoneal lymph nodes when imaging or intraoperative findings suggest spread beyond the peritoneal surfaces. Positive retroperitoneal nodes generally indicate more advanced disease and may influence both treatment recommendations and damages calculations in a legal claim, since prognosis and life expectancy are central to compensation for future medical care, pain and suffering, and lost income.

Example Sentence

During her cytoreductive surgery for peritoneal mesothelioma, the surgeon performed a limited retroperitoneal lymph node dissection after a suspicious node was identified on the preoperative CT scan.

Related Terms

Peritoneal Mesothelioma, Cytoreductive Surgery (CRS), HIPEC, Lymphadenectomy, Staging, Peritoneum

Notes

• Ask your surgical oncologist whether lymph node sampling or dissection is planned as part of your operation and how the findings will affect your treatment and prognosis.
• Request the full operative report and final pathology report, including the number of nodes removed and how many were positive. These details are important for both medical follow-up and any legal claim.
• If retroperitoneal nodes are positive, ask whether adjuvant chemotherapy, immunotherapy, or clinical trial enrollment is appropriate; this is also relevant evidence of disease severity in litigation.
• Preserve all imaging (CT, MRI, PET) that documents lymph node involvement, as these studies often become exhibits supporting damages in mesothelioma cases.